Abstract
Vancomycin Heteroresistance in Methicillin-resistant<i>Staphylococcus aureus</i>, Taiwan
Highlights
To the Editor: In 1997, Hiramatsu and colleagues reported the first clinical isolate of methicillin-resistant Staphylococcus aureus (MRSA) showing reduced susceptibility to vancomycin [1]
methicillin-resistant Staphylococcus aureus (MRSA) bacteremia relapsed in November 2001, and the patient received intravenous teicoplanin treatment (400 mg every 2 days) for 3 weeks, and fever resolved rapidly
MICs of vancomycin were determined for the 21 isolates of MRSA from the two patients (Table) by the broth microdilution and agar dilution method using brain-heart infusion (BHI) agar or broth and MuellerHinton agar (MHA) or broth (BBL Microbiology Systems, Cockeysville, MD), according to the recommendations by the National Committee for Clinical Laboratory Standards [5]
Summary
To the Editor: In 1997, Hiramatsu and colleagues reported the first clinical isolate of methicillin-resistant Staphylococcus aureus (MRSA) showing reduced susceptibility to vancomycin [1]. MRSA bacteremia relapsed in November 2001, and the patient received intravenous teicoplanin treatment (400 mg every 2 days) for 3 weeks, and fever resolved rapidly.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
